Having sold an interest in Talecris Biotherapeutics to Grifols SA, a Spanish company with worldwide biopharmaceutical and other medical businesses, Cerberus Capital chief Stephen Feinberg ended up with $422 million worth of Grifols shares.
It’s not clear how much cash Cerberus received in the deal in addition to the stock. Mr. Feinberg appears to have done well in the transaction, which closed a few weeks ago.
He may be completing Cerberus’ long-term Talecris saga by selling the Grifols shares. Or he might hold them for a while. Cerberus has owned healthcare and pharmaceutical businesses for extended periods.
Grifols, with new products in the pipeline, appears to be poised for growth. It announced a reorganization of its North American operations early this month following the Talecris acquisition.
Tags: Cerberus Capital, Grifols SA, Stephen Feinberg, Talecris Biotherapeutics
HedgeFundSmarts 
Leave a Reply